Latest Articles

Publication Date
Leven Rambin Says She Nearly Lost Her Life During Routine Surgery After Doctors Accidentally ‘Nicked’ Her Aorta - People.com

Leven Rambin Says She Nearly Lost Her Life During Routine Surgery After Doctors Accidentally ‘Nicked’ Her Aorta People.com

Published: July 15, 2026, 5:26 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga

Published: July 15, 2026, 5:25 p.m.
Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD - Contemporary OB/GYN

Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD Contemporary OB/GYN

Published: July 15, 2026, 5:16 p.m.
GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline - TipRanks

GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline TipRanks

Published: July 15, 2026, 4:46 p.m.
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset - Femtech Insider

New Flo and Mayo Clinic Research Finds Widespread Confusion About Perimenopause Onset Femtech Insider

Published: July 15, 2026, 12:41 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
The harshness of holding back: Pem on creating art through chronic illness - Far Out Magazine

The harshness of holding back: Pem on creating art through chronic illness Far Out Magazine

Published: July 15, 2026, 6 a.m.
Barbara Palvin, Dylan Sprouse expecting baby girl - Inquirer.net

Barbara Palvin, Dylan Sprouse expecting baby girl Inquirer.net

Published: July 15, 2026, 3:23 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!